ArticleFrontiers in medicine2026
Application of fine-needle aspiration biopsy combined with multi-gene testing in the differential diagnosis of benign and malignant C-TIRADS 4 thyroid nodules.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To explore the clinical value of fine-needle aspiration biopsy (FNAB) combined with multi-gene testing (including BRAF Methods: A total of 650 patients (650 nodules) with thyroid nodules who visited our hospital between January 2021 and December 2024 were included in this study. All patients underwent ultrasound-guided FNAB and multi-gene testing (including BRAF Results: Among the 650 thyroid nodules, 432 were malignant, and 218 were benign according to postoperative pathology reports. FNAB combined with multi-gene testing demonstrated improved sensitivity compared with FNAB alone, with a sensitivity of 91.0%, specificity of 76.15%, and accuracy of 86.0%. The AUC of the combined method was 0.836, which was significantly higher than that of FNAB alone (0.781) and multi-gene testing alone (0.806) ( Conclusion: FNAB combined with multi-gene testing significantly improves the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.